DSM - proposed appointment to the Managing Board of Directors
(Thomson Reuters ONE) -
The Supervisory Board of Royal DSM is pleased to announce that it will propose
to the Annual General Meeting of Shareholders on 28 April 2011 to appoint Mr.
Stefan Doboczky to the Managing Board of DSM with responsibility for DSM's
Pharma cluster as well as the regional responsibility of DSM's activities in
Asia, with effect from 1 May 2011.
Mr. Doboczky will operate from two office locations, in the Netherlands and in
Asia in line with the further internationalization of DSM, as set out in the
latest DSM strategy announced in September 2010.
Stefan Doboczky (1967), an Austrian national is at present President of the
Business Group DSM Anti-Infectives. He has built a strong track record within
the DSM Pharma cluster and has particular experience with business development
in high growth economies, including Asia. Before joining DSM in 1998, Mr.
Doboczky worked at ARCO Chemicals in Austria and the UK.
In DSM Mr. Doboczky held several senior positions in DSM Pharmaceutical
Products, before he became Vice President and Business Unit Director China for
DSM Anti-Infectives based in Beijing in 2006. In 2009 he became the President of
DSM Anti-Infectives.
Mr. Doboczky studied at the Technical University of Vienna, Austria and he holds
a Master in Chemistry and a PhD in Natural and Technical Sciences as well as an
MBA from IMD in Lausanne.
In view of the ongoing formation of the joint venture between DSM Anti-
Infectives and Sinochem, Mr. Doboczky will for the time being also continue in
his position as President DSM Anti-Infectives.
DSM - Bright Science. Brighter Living.(TM)
Royal DSM N.V. is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials. DSM's
22,000 employees deliver annual net sales of about ? 9 billion. The company is
listed on NYSE Euronext. More information can be found at www.dsm.com
For more information:
DSM Corporate Communications DSM Investor Relations
Herman Betten Hans Vossen
tel. +31 (0) 45 5782017 tel. +31 (0) 45 5782864
fax +31 (0) 45 5740680 fax +31 (0) 10 4590275
e-mail media.relations(at)dsm.com e-mail investor.relations(at)dsm.com
Press release-pdf:
http://hugin.info/130663/R/1492377/428158.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DSM N.V. via Thomson Reuters ONE
[HUG#1492377]
Unternehmensinformation / Kurzprofil:
Datum: 25.02.2011 - 08:15 Uhr
Sprache: Deutsch
News-ID 51904
Anzahl Zeichen: 3739
contact information:
Town:
Heerlen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM - proposed appointment to the Managing Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
DSM N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
